Applied Therapeutics Inc

Overview

Applied Therapeutics Inc (Applied Therapeutics) is a clinical-stage biopharmaceutical company. The company develops pipeline of drugs and molecular targets for diseases such as Galactosemia and Diabetic Cardiomyopathy (DbCM). Applied Therapeutics pipeline products include AT-001, a novel aldose reductase inhibitor (ARI) and AT-007, a SORD Deficiency, AT-001, a Diabetic Peripheral Neuropathy, a central nervous system penetrant ARI. It also develops preclinical pipeline product AT-003, an ARI designed for the treatment of diabetic retinopathy and AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukaemia. Applied Therapeutics is headquartered in New York City, New York, the US.
Key Stats
Address
545 5TH AVENUE, SUITE 1400, NEW YORK, New York
Headquarters

United States of America

Contact

1 212 2209319

No of Employees

24

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

APLT [NASD]

Net Income (2020)

$-94 m

-106.6% (2020 vs 2019)
Market Cap *

$401 m

EPS *

$-4.3

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Applied Therapeutics IncSage Therapeutics IncPhaseBio Pharmaceuticals Inc
Key Information
Headquarters United States of America United States of America United States of America
Headquarter City NEW YORK CAMBRIDGE MALVERN
Headquarter State/Province New York Massachusetts Pennsylvania
No. of Employees 24 298 55
Entity Type Public Public Public

Products & Services

Applied Therapeutics engages in developing a pipeline of novel product candidates. Key products offered by the company include:

Products
  • AT-001 Pipeline
  • AT-003 Pipeline
  • AT-007 Pipeline
  • Vitae Eget Libero

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Stock Listings/IPO In June, the company secured the US FDA fast track designation to AT-007 for the…
2019 Stock Listings/IPO In April, the company announced its plans to raise US$86 million in IPO of shares.
2017 Financing Agreements In February, the company secured a series A financing round from a group of investors.
2016 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
10 Feb 2021 Applied Therapeutics Raises USD79.4 Million in Public Offering of Shares Equity Offering Applied Therapeutics Inc
21 Apr 2020 Applied Therapeutics to Raise Funds through Public Offering of Common Stock Equity Offering Applied Therapeutics Inc
21 Jan 2020 Applied Therapeutics Raises USD143.4 Million in Public Offering of Shares Equity Offering Applied Therapeutics Inc
13 Dec 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
12 Nov 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
21 Jun 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit